ArticleFrontiers in cellular and infection microbiology2026
Impact of pathophysiologically relevant underlying disease burden on pathogen distribution and antimicrobial resistance in patients with device-associated urinary tract infections.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the impact of pathophysiologically relevant underlying disease burden on the distribution of pathogenic bacteria and antimicrobial resistance in patients with device-associated urinary tract infections (DA-UTIs), and to provide evidence for precise empirical therapy and infection prevention and control in high-risk populations. Methods: Only underlying diseases with known pathophysiological relevance to urinary tract infection (e.g., diabetes mellitus, urinary stones/obstruction, renal insufficiency, etc.) were considered. A retrospective study was conducted on 449 patients with DA-UTIs admitted to the Affiliated Hospital of Xuzhou Medical University from January 2020 to December 2024. Patients were stratified into three groups according to the number of underlying diseases: Group A (no underlying diseases), Group B (one underlying disease), and Group C (≥2 underlying diseases). Clinical manifestations and pathogenic spectrum composition were compared among the three groups, and the antimicrobial resistance characteristics of Results: The median age of the patients was 66 years, and most patients were admitted to the Department of Urology and Intensive Care Unit (ICU). Conclusion: In patients with DA-UTIs, pathophysiologically relevant underlying disease burden is closely associated with antimicrobial resistance of pathogenic bacteria, particularly significantly increasing the risk of fluoroquinolone resistance. Routine use of fluoroquinolones should be avoided in such high-risk patients for clinical empirical therapy. The initial treatment regimen should be optimized and etiological testing should be strengthened based on local antimicrobial resistance surveillance data and the patient's comorbidity status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.